# Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

> **NCT05501561** · PHASE2 · COMPLETED · sponsor: **Seqirus** · enrollment: 1056 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1
- **BIOLOGICAL:** Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1
- **BIOLOGICAL:** Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1
- **BIOLOGICAL:** Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1

## Key facts

- **NCT ID:** NCT05501561
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-25
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 1056 (ACTUAL)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05501561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05501561, "Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05501561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*